Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Review Article Volume 6 Issue 6

An Update on Osteosarcoma

Zeenat Ara1, Sandeep Pandey2,Shatakshi Pant1, Ramesh mani Tripathi2 and Shahwaliullah1*

1Department of Orthopaedic Surgery, King George’s Medical University, Lucknow
2Department of Biochemistry King George's Medical University, Lucknow

*Corresponding Author: Shah Walliullah,Department of Orthopaedic Surgery, King George’s Medical University, Lucknow, Uttar Pradesh, India.

Received: August 21, 2022; Published: September 30, 2022

Abstract

Following lymphomas and brain malignancies, osteosarcomas are the most prevalent primary bone tumours in children and adolescents. The development of osteoid, or immature bone, by malignant mesenchymal cells serves as its defining characteristic. However the cause of the OS is still unknown, however in children, the disease appears to be sporadic. Genetics also plays major role in OS, thus This article examines the origin, clinical manifestation, diagnostic procedures, and treatment of osteosarcoma. Adjuvant chemotherapy was introduced in the 1970s, increasing patient 10-year survival from 30% to around 50% as a result of tumour excision. The first step to enhancing these figures is a greater comprehension of this illness.

Keywords: Osteosarcomas; Pagets Disease; Malignant Mesenchymal Cells; Tumour; Osteoid; Limb Salvage; Osteoblast, Plain Radiograph; Computed Tomography; MRI; MFH (Malignant Fibrous Histiocytoma)

References

  1. Meyers PA., et al. “Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group”. Journal of Clinical Oncology4 (2008): 633-638.
  2. Marulanda GA., et al. “Proximal and total humerus reconstruction with the use of an aortograft mesh”. Clinical Orthopaedics and Related Research® 468.11 (2010): 2896-2903.
  3. Casali PG., et al. “Chordoma”. Current Opinion in Oncology4 (2007): 367-370.
  4. Jeong JO., et al. “Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy”. Circulation Research11 (2011): 1340-1347.
  5. Stacchiotti S., et al. “Phase II study of imatinib in advanced chordoma”. Journal of Clinical Oncology9 (2012): 914-920.
  6. Tarpey PS., et al. “Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma”. Nature Genetics8 (2013): 923-926.
  7. Walcott BP., et al. “Chordoma: current concepts, management, and future directions”. The Lancet Oncology2 (2012): e69-76.
  8. Stiller CA., et al. “Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project”. European Journal of Cancer 42 (2006a): 2124-2135.
  9. McKenna RJ., et al. “Sarcomata of osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone): an analysis of 552 cases”. Journal of Bone and Joint Surgery. American Volume 48-A (1996): 1-26.
  10. Nguyen A., et al. “Roles of bone morphogenetic protein signaling in osteosarcoma”. International Orthopaedics11 (2014): 2313-2322.
  11. Fletcher CD., et al. “Osteogenic tumours. World Health Organization classification of tumours; Pathology and genetics of tumours of soft tissue and bone”. (2002): 259-290.
  12. Bielack SS., et al. “Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols”. Journal of Clinical Oncology3 (2002): 776-790.
  13. Meyers P. “Prognostic factors for sarcomas: Hard and soft”. Journal of Clinical Oncology 20 (2002): 627-629.
  14. Hayden JB and Hoang BH. “Osteosarcoma: basic science and clinical implications”. Orthopaedic Clinics of North America 37 (2006): 1-7.
  15. Trost ME., et al. “Primary bone neoplasms in dogs: 90 cases”. Pesquisa Veterinária Brasileira 32 (2012): 1329-1335.
  16. Bacci G., et al. “High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study”. Journal of Chemotherapy2 (2002): 198-206.
  17. Harvei S and Solheim Ø. “The prognosis in osteosarcoma: Norwegian national data”. Cancer 48 (1981): 1719-1723.
  18. Simon MA., et al. “Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur”. Journal of Bone and Joint Surgery. American Volume 68 (1986): 1331-1337.
  19. Rougraff BT., et al. “Limb salvage compared with amputation for osteosarcoma of the distal end of the femur: a long-term oncological, functional, and quality-of-life study”. Journal of Bone and Joint Surgery. American Volume5 (1994): 649-656.
  20. Mirabello L., et al. “Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results program”. Cancer7 (2009): 1531-1543
  21. Mirabello L., et al. “Height at diagnosis and birth-weight as risk factors for osteosarcoma”. Cancer Causes and Control6 (2011): 899-908.
  22. Longhi A., et al. “Height as a risk factor for osteosarcoma”. Journal of Pediatric Hematology/Oncology6 (2005): 314-318.
  23. Linabery AM and Ross JA. “Trends in childhood cancer incidence in the U.S. (1992-2004)”. Cancer 112 (2008): 416-32.
  24. Bleyer A., et al. “Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials”. Cancer: Interdisciplinary International Journal of the American Cancer SocietyS7 (2006): 1645-1655.
  25. Polednak AP. “Primary bone cancer incidence in black and white residents of New York State”. Cancer 55 (1985): 2883-2888.
  26. Polednak AP. “Bone cancer among female radium dial workers. Latency periods and incidence rates by time after exposure: brief communication”. Journal of the National Cancer Institute 60 (1978a): 77-81.
  27. Picci P. “Osteosarcoma: What did we learn from the paediatric experience for adolescents and young adults?”. European Journal of Cancer Supplements5 (2007): 227-234.
  28. Rani AS and Kumar S. “Transformation of non-tumorigenic osteoblast-like human osteosarcoma cells by hexavalent chromates: alteration of morphology, induction of anchorage-independence and proteolytic function”. Carcinogenesis 11 (1992): 2021-2027.
  29. F R Dutra and E J Largent. “Osteosarcoma induced by beryllium oxide”. American Journal of Pathology2 (1950): 197-209.
  30. “Experimental production of bone sarcomas in the rabbit by a single local injection of beryllium”. Bulletin du Cancer 62.1 (1975): 49-58.
  31. M L Tan., et al. “Osteosarcoma: conventional treatment vs. gene therapy”. Cancer Biology and Therapy2 (2009): 106-117.
  32. J Smida., et al. “Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma”. Clinical Cancer Research16 (2010): 4256-4267.
  33. H T Ta., et al. “Osteosarcoma treatment: state of the art”. Cancer and Metastasis Reviews1-2 (2009): 247-263.
  34. Marina N., et al. “Biology and therapeutic advances for pediatric osteosarcoma”. The Oncologist4 (2004): 422-441.
  35. B Alberts., et al. “Molecular biology of the cell”. Garland Science (2008).
  36. Longhi A. “Osteosarcoma in blood relatives”. Oncology Report 8 (2001): 131-136.
  37. Wu JX., et al. “The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas”. Oncogene 7 (1990): 989-1000.
  38. Gamberi G., et al. “C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression”. Oncology 55 (1998): 556-563.
  39. Shimizu T., et al. “c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis”. Oncogene42 (2010): 5687-5699.
  40. Hettinger K., et al. “c-Jun promotes cellular survival by suppression of PTEN”. Cell Death and Differentiation2 (2007): 218-229.
  41. Rikhof B., et al. “The insulin‐like growth factor system and sarcomas”. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland4 (2007): 469-482.
  42. Errani C., et al. “Palliative therapy for osteosarcoma”. Expert Review of Anticancer Therapy2 (2011): 217-227.
  43. Meyers PA., et al. “Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group”. Journal of Clinical Oncology4 (2008): 633-638.

Citation

Citation: Shah Walliullah., et al. “An Update on Osteosarcoma" Acta Scientific Cancer Biology 6.6 (2022): 26-39.

Copyright

Copyright: © 2022 Shah Walliullah., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.183

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US